US 11,918,604 B2
Chimeric antigen receptor dendritic cell (CAR-DC) for treatment of cancer
Samuel C. Wagner, San Diego, CA (US); Thomas E. Ichim, San Francisco, CA (US); Julia S. Szymanski, San Diego, CA (US); Santosh Kesari, San Diego, CA (US); Amit N. Patel, Salt Lake City, UT (US); and Boris Minev, San Diego, CA (US)
Assigned to MYELOID THERAPEUTICS, INC., Cambridge, MA (US)
Filed by Myeloid Therapeutics, Inc., Cambridge, MA (US)
Filed on Apr. 7, 2022, as Appl. No. 17/715,710.
Application 17/715,710 is a continuation of application No. 17/559,967, filed on Dec. 22, 2021.
Application 17/559,967 is a continuation of application No. 17/227,193, filed on Apr. 9, 2021, abandoned.
Application 17/227,193 is a continuation of application No. 15/048,922, filed on Feb. 19, 2016, abandoned.
Claims priority of provisional application 62/118,027, filed on Feb. 19, 2015.
Prior Publication US 2022/0233586 A1, Jul. 28, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/0786 (2010.01); A61K 35/15 (2015.01); A61K 38/17 (2006.01); C07K 16/00 (2006.01); C07K 16/30 (2006.01); C07K 16/32 (2006.01)
CPC A61K 35/15 (2013.01) [A61K 38/177 (2013.01); C07K 16/00 (2013.01); C07K 16/30 (2013.01); C07K 16/32 (2013.01); C12N 5/0645 (2013.01); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01); C12N 2501/599 (2013.01); C12N 2510/00 (2013.01)] 25 Claims
 
1. A method of making a population of chimeric antigen receptor (CAR) encoded CD14+ cells, the method comprising:
(a) extracting a leukapheresis sample or a PBMC sample from a human subject;
(b) isolating CD14+ cells from CD3+ cells in the leukapheresis sample from (a) or the PBMC sample from (a);
(c) after (b), culturing the isolated CD14+ cells ex vivo in the presence of (i) a growth factor, wherein the growth factor comprises recombinant human M-CSF and does not comprise GM-CSF and (ii) a cytokine that does not comprise IL-2,
 thereby obtaining an ex vivo population of CD14+ cells; and
(d) introducing a recombinant polynucleic acid encoding a chimeric antigen receptor (CAR) into the ex vivo population of CD14+ cells, thereby obtaining the population of CAR encoded CD14+ cells;
wherein the CAR comprises (i) an extracellular domain comprising an antigen binding domain; (ii) a transmembrane domain; and (iii) an intracellular domain comprising a CD3 zeta intracellular signaling domain.